Kim Won, Yoon Jung-Hwan, Jeong Jae-Min, Cheon Gi-Jeong, Lee Tae-Sup, Yang Jong-In, Park Su-Cheol, Lee Hyo-Suk
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Mol Cancer Ther. 2007 Sep;6(9):2554-62. doi: 10.1158/1535-7163.MCT-07-0115.
Hypoxia stimulates hepatocellular carcinoma (HCC) cell growth via hexokinase (HK) II induction, and alternatively, HK II inhibition induces apoptosis by activating mitochondrial signaling. This study was to investigate whether the induction of HK II by hypoxia is associated with enhanced mitochondrial stability and to confirm the apoptosis-inducing efficacy of HK II inhibitor in an in vivo model of HCC. Mitochondrial stability was examined by treating isolated mitochondria with deoxycholate, a permeability-enhancing agent. Alteration of permeability transition pore complex composition was analyzed by immunoprecipitation and immunoblotting. An in vivo model of HCC was established in C3H mice i.d. implanted with MH134 cells. The antitumor efficacy of i.p. given 3-bromopyruvate (3-BrPA), a HK II inhibitor, was evaluated by measuring tumor volumes and quantifying apoptosis using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining and (99m)Tc-hydrazinonicotinamide-Annexin V scans. Hypoxia enhanced mitochondrial stability, and this was inhibited by 3-BrPA treatment. In particular, HK II levels in permeability transition pore complex immunoprecipitates were reduced after 3-BrPA treatment. In mice treated with 3-BrPA, mean tumor volumes and tumor volume growth were found to be significantly reduced. Moreover, percentages of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells were significantly increased in 3-BrPA-treated mice, and this apoptosis-inducing efficacy was reflected in vivo by (99m)Tc-hydrazinonicotinamide-Annexin V imaging. Our results show that hypoxia enhances mitochondrial stability via HK II induction and that HK II inhibitor treatment exhibits an in vivo antitumor effect by inducing apoptosis. Therefore, HK II inhibitors may be therapeutically useful for the treatment of advanced infiltrative hypovascular HCCs, which are growing in a hypoxic environment.
缺氧通过诱导己糖激酶(HK)II刺激肝细胞癌(HCC)细胞生长,相反,HK II抑制通过激活线粒体信号传导诱导细胞凋亡。本研究旨在探讨缺氧诱导HK II是否与线粒体稳定性增强有关,并在HCC体内模型中证实HK II抑制剂的诱导凋亡疗效。通过用脱氧胆酸盐(一种通透性增强剂)处理分离的线粒体来检测线粒体稳定性。通过免疫沉淀和免疫印迹分析通透性转换孔复合物组成的改变。在C3H小鼠皮下植入MH134细胞建立HCC体内模型。通过测量肿瘤体积并使用末端脱氧核苷酸转移酶介导的dUTP缺口末端标记染色和(99m)Tc-肼基烟酰胺-膜联蛋白V扫描定量凋亡来评估腹腔注射HK II抑制剂3-溴丙酮酸(3-BrPA)的抗肿瘤疗效。缺氧增强了线粒体稳定性,而3-BrPA处理可抑制这种增强。特别是,3-BrPA处理后,通透性转换孔复合物免疫沉淀物中的HK II水平降低。在用3-BrPA处理的小鼠中,发现平均肿瘤体积和肿瘤体积生长显著减少。此外,在3-BrPA处理的小鼠中,末端脱氧核苷酸转移酶介导的dUTP缺口末端标记阳性细胞的百分比显著增加,并且这种诱导凋亡的疗效通过(99m)Tc-肼基烟酰胺-膜联蛋白V成像在体内得到反映。我们的结果表明,缺氧通过诱导HK II增强线粒体稳定性,并且HK II抑制剂治疗通过诱导凋亡表现出体内抗肿瘤作用。因此,HK II抑制剂可能对治疗在缺氧环境中生长的晚期浸润性低血供HCC具有治疗作用。